Posted: May 15, 2013 at 12:45 am
Are all stem cells that can be used to treat osteoarthritis the same?
http://www.stemcellsarthritistreatment.com Although stem cells isolated from different tissues show similar physical characteristics, it is not clear whether these are the same stem cells....
By: Nathan Wei
Read the rest here:
Are all stem cells that can be used to treat osteoarthritis the same? - Video
Posted: May 14, 2013 at 10:08 pm
As the California stem cell agency
pushes ever more aggressively to turn research into cures, the second
largest share of its awards, in terms of numbers of grants, has gone
to efforts involving induced pluripotent cells, also known as
reprogrammed adult cells.
“All the talk and the slew of
publications about potentially using iPS cells to develop therapies
to help patients is exciting in theory, but unfortunately the reality
is that it is not entirely clear if most researchers are, from a
legal standpoint, even allowed to develop and commercialize iPS
cell-based therapies at all.
“The patent landscape for iPS cells
is complicated to put it mildly. A
Google patent search for “induced pluripotent stem cells”
produced almost 200,000 results.
“A search for “cellular
reprogramming produced more than 1,000
results.
I’m not sure all of these results are
really separate patents, but still….that’s a big complicated
mess.…..
“It is no exaggeration to say
there are likely dozens of institutions around the world wanting to
commercialize iPS cell-based products.
“Will they all have to pay expensive
licensing fees or end up in court?
…or will the patent holders
voluntarily and freely allow others to commercialize iPS cell-based
medical treatments?
“I don’t think so.
“This could get really messy.”
Posted: May 14, 2013 at 6:31 pm
“I must take issue with your entry,
'Robert Klein Gives $21,630 to the California Stem Cell Agency,' May
05, 2013.
“When
Bob Klein donated $21,630 to the California stem cell program (to
allow scientists to attend a research conference in Japan) he was
doing exactly what he always does: advancing research to ease
suffering and save lives. The scientists needed a way to attend
a top-level conference. Believing in the benefits of researchers
sharing thoughts, Bob paid for their trip.
“Unfortunately,
your article appears to imply corrupt motivations.
“'A
seemingly innocuous…gift…generated a wave of special favors for
(Klein) that stretched out to include a gold mining multimillionaire
from Canada.'.
A 'wave of special favors?' The article
states that 'Klein wanted to meet with the six science officers…'
and to get their impressions on the conference.
“Is
that not natural? First, would it not be helpful to hear from the
scientists if the trip was worth the time and expense? Second, Bob
Klein works in real estate, a full-time job. He does not have the
scientist’s automatic involvement to keep him up to speed on
everything new in regenerative research. But he wants to know the
latest: what is working, what is not. He is always eager for a chance
to speak one-on-one with an expert.
“He met with a Canadian
millionaire? Why is this shocking? The millionaire supports stem cell
research; so does Bob. California is working closely with Canada on
several projects; they pay their scientists, we pay ours; more bang
for the buck. If there is a person with the resources and will to
advance Canadian research, it is natural that Bob would want to
develop a deeper interest in the shared research.
“And why
should Klein be criticized for supporting a research project
attempting to alleviate Alzheimer’s? He saw his own mother die of
the disease, after losing the ability to recognize her own son.
I am familiar with that particular Alzheimer’s project, and
it had some amazing results, restoring memory to laboratory rats.
This was a water maze test, and the rats recovered the memory of a
pathway out of the water, which they had forgotten. To the best of my
knowledge, no one else in the world had achieved memory return, and
the project deserved the most serious consideration. Yes, the
board of directors voted against the Grants Working Group; it is not
only their right but their responsibility to exercise judgment, and
not merely be a rubber stamp for the GWG.
“There is also the
matter of free speech. Anybody else in California can come to the
meetings of the program and voice their opinion—why should Klein be
denied the right to voice his opinion?
“Bob Klein owns no
stem cell stock, no biomedical enterprises. Financially, supporting
stem cell research has cost him a great deal. This is the man who led
the fight to build the California stem cell program, donating roughly
six million dollars, taking out loans on his house to help finance
Proposition 71. And, for six years (without salary) he worked
full-time as Chair of the Board of the oversight committee.
Physically and emotionally, it has been an exhausting decade for him.
He has not profited in any way, except to see the advancement of
research for cure.
“Passing a $3 billion stem cell program
in the midst of a recession was like relocating Mount
Everest—seemingly impossible, but he did it anyway. He moved the
mountain. Thousands of people helped, but one man made it possible.
Without Bob Klein, California would not have the greatest stem cell
program in the world: challenging diseases considered incurable since
the dawn of time. That he should continue to support it, with his
dollars, time, energy and creativity, is commendable.
“Sometimes
a good deed is just that: no sinister motivations, no secret
agendas-- just a positive action which benefits all.”
Posted: May 14, 2013 at 5:47 pm
What are, and how we use Stem Cells
How we use Stem Cells To find out more visit: buydirectonline.jeunesseglobal.com.
By: jeunessebuydirect
Continued here:
What are, and how we use Stem Cells - Video
Posted: May 14, 2013 at 5:47 pm
GOLDEN, Colo. (CBS4) In an effort to live a long and healthy life, some adults are now taking out a different kind of insurance policy. They are banking their stem cells for future use.
CBS4 Health Specialist Kathy Walsh watched one man go through the process. Its relatively simple but it can set a person back several thousand dollars. Still, one retired engineer believes it is worth the investment.
I am just a 54-year-old whos trying to figure out how to get the most out of life, Matt Rockwell said. Were told that we can live, at least machinery wise, we can live to 120. Id like my 120.
In fact, Rockwell is banking on that. In his doctors office in Golden, he is saving cells. Five vials of blood were collected. Then, Dr. Terry Grossman took a small sample of Rockwells skin cells.
Grossman practices nutritional and anti-aging medicine and has written three books about longevity.
Right now, stem cell therapies are in their infancy, Grossman said.
But Grossman believes the possibilities are endless.
Whats going to be available in 10 to 20 years, it boggles the imagination, he said.
So Grossman collects stem cells for patients and sends them away to be grown and cryopreserved. The belief is they may later be used to treat various diseases or conditions.
Animals are having wonderful results and we are able to create, for instance, rat hearts and mouse hearts; and we are able to grow new cartilage for race horses, Grossman said.
Read this article:
Some People Banking Stem Cells For Future Use To Stay Healthy
Posted: May 14, 2013 at 5:47 pm
Tuesday, May 14th, 2013 Issue 20, Volume 17.
RIVERSIDE - A UC Riverside professor will give a free lecture about stem cells at UCR's Extension Center later this month, a campus spokesman said today.
The May 30 lecture, "Promise of Stem Cells: Hope or Hype?" will be given by Nicole zur Nieden, an assistant professor of cell biology and neuroscience at UCR.
Zur Nieden will discuss whether stem cells -- which can become specialized cells with specific functions and can be used to regenerate and repair diseased or damaged tissues -- are a "miracle cure," Advertisement [ Pala Mesa Resort ] according to UCR spokesman Iqbal Pittalwala.
Zur Nieden, a biologist and expert in stem cell biology, toxicology and bioengineering, is a member of UCR's Stem Cell Center. Her research group is working to understand how embryonic stem cells develop into bone tissue, Pittalwala said.
The 5:30 p.m. lecture is the fourth and last talk in the annual Science Lecture Series hosted by the College of Natural and Agricultural Sciences. This year's theme is "The Science of Disease."
Seating for the lecture is open, and parking is free.
See more here:
Free lecture on regeneration of damaged tissues with stem cells offered at UC Riverside
Posted: May 14, 2013 at 5:47 pm
DUBLIN--(BUSINESS WIRE)--
Research and Markets (http://www.researchandmarkets.com/research/3724fc/mesenchymal_stem) has announced the addition of the "Mesenchymal Stem Cells - Advances & Applications 2013" report to their offering.
Understand and profit from the mesenchymal stem cell (MSC) product market - the fastest growing area of stem cell research.
Updated to reflect the most current trends and including five year market projections, this report focuses on the advances in MSC research. In 125 pages you'll explore research priorities by market segment, highlight individual labs and end-users of MSC products, understand the competitive environment for such products and discover market-leading trend analysis.
Revealing Unique Strategic Opportunities & Unknown Competitive Advantages
MSCs are advantageous over other stem cells types for several reasons. First, they avoid the ethical issues that surround embryonic stem cell research. Second, repeated studies have found that human MSCs are immuno-privileged, and therefore, represent an advantageous cell type for allogenic transplantation, reducing the risks of rejection and complications of transplantation. Recently, there have also been significant advances in the use of autologous MSCs to regenerate human tissues, including cartilage and meniscus, tendons, and bone fractures.
This market research report focuses on recent advances in MSC research applications, explores research priorities by market segment, highlights individual labs and end-users of MSC research products, explores the competitive environment for MSC research products, and provides 5-year growth and trend analysis. The report advantageously positions companies that wish to offer competitive stem cells products to this rapidly growing, well-funded research community.
Expanded and Updated Market Intelligence
This is an expanded and updated market intelligence report that includes:
- Updated Charts, Timelines, Metrics and Financials
Originally posted here:
Research and Markets: Mesenchymal Stem Cells - Advances & Applications 2013
Posted: May 14, 2013 at 5:47 pm
May 14, 2013 In new research published online May 13, 2013 in Advanced Materials, researchers from Brigham and Women's Hospital (BWH) are the first to report that synthetic silicate nanoplatelets (also known as layered clay) can induce stem cells to become bone cells without the need of additional bone-inducing factors. Synthetic silicates are made up of simple or complex salts of silicic acids, and have been used extensively for various commercial and industrial applications, such as food additives, glass and ceramic filler materials, and anti-caking agents.
"With an aging population in the US, injuries and degenerative conditions are subsequently on the rise," said Ali Khademhosseini, PhD, BWH Division of Biomedical Engineering, senior study author. "As a result, there is an increased demand for therapies that can repair damaged tissues. In particular, there is a great need for new materials that can direct stem cell differentiation and facilitate functional tissue formation. Silicate nanoplatelets have the potential to address this need in medicine and biotechnology."
"Based on the strong preliminary studies, we believe that these highly bioactive nanoplatelets may be utilized to develop devices such as injectable tissue repair matrixes, bioactive fillers, or therapeutic agents for stimulating specific cellular responses in bone-related tissue engineering," said Akhilesh Gaharwar, PhD, BWH Division of Biomedical Engineering, first study author. "Future mechanistic studies will be performed to better understand underlying pathways that govern favorable responses, leading to a better understanding of how materials strategies can be leveraged to further improve construct performance and ultimately shorten patient recovery time."
Share this story on Facebook, Twitter, and Google:
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by Brigham and Women's Hospital, via EurekAlert!, a service of AAAS.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Journal Reference:
Note: If no author is given, the source is cited instead.
More:
Using clay to grow bone: Researchers use synthetic silicate to stimulate stem cells into bone cells
Posted: May 14, 2013 at 5:47 pm
In free public lecture on May 30 at UC Riverside stem-cell expert Nicole zur Nieden will discuss the enthusiasm and caveats surrounding stem cell therapy
By Iqbal Pittalwala on May 14, 2013
Nicole zur Nieden is an assistant professor of cell biology and neuroscience at UC Riverside. Photo credit: Zur Nieden Lab, UC Riverside.
RIVERSIDE, Calif. Stem cells are mother cells that can become specialized cells with a more specific function, such as brain cells, blood cells, heart muscle or bone. Because they can be used to regenerate and repair diseased or damaged tissues in people, they have, at times, been portrayed as a miracle cure for a variety of conditions and disabilities.
But are they the miracle cure? Or is that an exaggeration? How do we separate fact from fiction and hope from hype when it comes to stem cell therapy?
Nicole zur Nieden, an assistant professor of cell biology and neuroscience at the University of California, Riverside, will give a free public lecture at UC Riverside on May 30 in which she will discuss whether the claims for stem cells can be justified.
Her hour-long talk is titled The promise of stem cells: Hope or hype? It will begin at 5:30 p.m. in Rooms C, D and E, University Extension Center (UNEX). Seating is open. Parking at UNEX is free for lecture attendees.
The lecture is the fourth and final talk in the annual Science Lecture Series hosted by the College of Natural and Agricultural Sciences (CNAS). This year the theme is The Science of Disease. The series aims to boost the publics awareness and understanding of science and of how scientists work.
Zur Nieden, a biologist by training with expertise in stem cell biology, toxicology and bioengineering, joined UCR in 2008. She is a member of UCRs Stem Cell Center. Her research group has established that functioning skeletal cell types are generated from embryonic stem cells, and has developed a comprehensive analysis of the expression of bone marker genes and enzymatic activity specific to bones.
Currently, her group is working to understand how embryonic stem cells develop into bone tissue. Her lab also is attempting to understand molecular regulators of normal bone development, and to deduce new therapeutic targets, which could be pinpointed during disease intervention in the clinic.
More here:
Stem Cells: Hope or Hype?
Posted: May 14, 2013 at 5:47 pm
Neuromics and Vitro Biopharma Expand Collaboration to Target Drug Discovery and Regenerative Medicine Markets
Golden, Colorado - Vitro Diagnostics, Inc. (VODG), dba Vitro Biopharma, announced expansion of its distribution agreement with Neuromics to include targeted sales to select markets in drug discovery & regenerative medicine. Early stages of drug development rely on in-vitro assays to identify effective new drugs and these assays are based on cellular systems. Vitro Biopharmas proprietary stem cell technology allows cost-effective manufacturing of stem cell-derived human cells and multi-cellular constructs that reflect the human in-vivo environment. We have recently developed stem cell-derived cartilage and bone producing cells called chondrocytes and osteoblasts together with various media formulations. We are now offering cells, media and custom services including genetically-engineered cells, to the biopharmaceutical industry specifically focused on drug discovery, development and toxicology for osteoporosis, Pagets disease, osteogenesis imperfecta, bone regeneration & accelerated healing of bone fractures.
This advancement allows us to now combine the distribution channels and sales/marketing expertise of Neuromics with Vitro Biopharmas proprietary technology and manufacturing to target additional markets beyond those presently being pursued in research and clinical development. In addition to markets in drug discovery, we are also pursuing select opportunities within regenerative medicine initially related to expanded use of our high performance and highly competitive MSC-Gro clinical grade media in the expansion of MSCs prior to therapeutic use. Vitro Biopharma is also developing novel stem cell-based products targeting regenerative medicine applications in animals including horses and dogs initially targeting treatment of articular injury, diseases and age-related degeneration.
Pete Shuster, the CEO of Neuromics said, Vitro Biopharmas products have performed well in the hands of our customers. We have years of experience providing primary and progenitor cells to basic and drug discovery researchers and know the importance of having best in class products and services for growing my business.
We now have the opportunity to expand into serving drug discovery for diseases that will need more cost effective treatments with our aging populations. Regenerative therapies using stem cells could prove to the silver bullet. We are working hard to everyday to make this possible
Dr Jim Musick, Vitro Biopharmas CEO, said, We are very pleased to announce our expanded relationship with Neuromics, Inc who has assisted us considerably to expand revenue generated from our products. Our new initiative is fueled by our development of stem-cell derived, differentiated cells including bone/cartilage producing osteoblasts and chondrocytes together with related media products to support use of these cellular systems in the discovery of new drugs for treatment of muscular skeletal diseases such as osteoporosis. While there are several existing drugs for use in treatment of osteoporosis there is a need for new, more effective and safer drugs especially targeting anabolic processes that promote bone generation. Our stem-cell derived human osteoblasts are ideally-suited for use in discovery of new drugs to promote osteoblast function and age-related diminished osteoblast function is a key factor in the generation of osteoporosis. Vitro Biopharma also owns proprietary technology that expands differentiation capacity of adult stem cells to pluripotent levels thus enabling us to expand our offerings of human stem cell derived cellular systems for drug discovery/development applications.
About Neuromics, Inc Neuromics (http://www.neuromics.com), located in Minneapolis, MN, is a privately-held, profitable and growing bio-reagents company. The company was initially built by supplying bio-markers to Neuroscience Researchers. Today, Neuromics provides a range of solutions that include markers, growth factors, gene expression analysis tools, apoptosis detection kits, primary cells and related media. These solutions are increasingly being used in combinations by customers to help accelerate or improve the process of drug discovery. Through the expanded association with Vitro Biopharma, the reagents offered by Neuromics for drug discovery will enhance the capabilities to serve this market sector.
About Vitro Biopharma Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB: VODG; http://www.vitrobiopharma.com), owns US patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. In 2011, Vitro Biopharma out-licensed its intellectual property related to treatment of infertility to Dr. James Posillico, a renowned expert in Assisted Reproductive Technologies. Vitro Biopharma also owns a pending US patent for generation of pluripotent stem cells and an additional pending patent for methods of mesenchymal stem cell (MSC) generation and related materials. Vitro Biopharmas mission is Harnessing the Power of Cells for the advancement of regenerative medicine to its full potential. Vitro Biopharma operates within a modern biotechnology manufacturing, R&D and corporate facility in Golden, Colorado. Vitro Biopharma manufactures and sells Tools for Stem Cell and Drug Development, including human mesenchymal stem cells and derivatives, the MSC-Gro Brand of optimized media for MSC self-renewal and lineage-specific differentiation. In addition to our FSH patent licensee, Vitro Biopharma maintains several strategic partnerships including an alliance with Neuromics, Inc. (www.neuromics.com). Neuromics, Inc. is a primary distributor of Vitro Biopharma products and a well established manufacturer and distributor of a large variety of life science research products especially focused on cell-based assay systems We jointly manufacture stem cell assay systems with HemoGenix, Inc. (http://www.hemogenix.com/), known as the LUMENESC quantitative assay for determination of MSC quality, potency and response to toxic agents. Vitro Biopharma has an agreement with Stemgenesis, Inc. (http://www.stemgenesisinc.com) for distribution of its stem cell products into select Chinese provinces. Also, Vitro Biopharmas CEO is a consultant on an NSF grant at the City College of New York to advise Dr. Lane Gilcrest, Professor of Materials Science and Engineering, and his colleagues regarding the development of novel extracellular materials for use in self-renewal and differentiation of mesenchymal stem cells.
Safe Harbor Statement Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as intends, anticipates, believes, expects and hopes and include, without limitation, statements regarding the Companys plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Companys products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Companys filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Dr. James Musick Chief Executive Officer Vitro Biopharma (303) 999-2130 Ext. 3 E-mail: jim@vitrobiopharma.com
The rest is here:
Neuromics and Vitro Biopharma Expand Collaboration to Target Drug Discovery and Regenerative Medicine Markets
Source:
Source: